BACKGROUND: Transsphenoidal selective adenomectomy is the first-line treatment for Cushing's disease. At experienced centers, early remission rates after transsphenoidal surgery range from 65 to 98%, however disease relapse frequently occurs with rates ranging from 2 to 35% at long-term follow up. METHODS: This article discusses recently reported studies on the surgical outcomes from transsphenoidal surgery for Cushing's disease. CONCLUSIONS: One of the keys to a successful long-term surgical outcome is meticulous dissection using the adenoma's pseudocapsule as a surgical plane for complete resection. MRI-negative and invasive ACTH-secreting adenomas pose particular challenges for pituitary surgeons.
BACKGROUND: Transsphenoidal selective adenomectomy is the first-line treatment for Cushing's disease. At experienced centers, early remission rates after transsphenoidal surgery range from 65 to 98%, however disease relapse frequently occurs with rates ranging from 2 to 35% at long-term follow up. METHODS: This article discusses recently reported studies on the surgical outcomes from transsphenoidal surgery for Cushing's disease. CONCLUSIONS: One of the keys to a successful long-term surgical outcome is meticulous dissection using the adenoma's pseudocapsule as a surgical plane for complete resection. MRI-negative and invasive ACTH-secreting adenomas pose particular challenges for pituitary surgeons.
Authors: Robert J Weil; Alexander O Vortmeyer; Lynnette K Nieman; Hetty L Devroom; John Wanebo; Edward H Oldfield Journal: J Clin Endocrinol Metab Date: 2006-04-24 Impact factor: 5.958
Authors: Jay Jagannathan; Rene Smith; Hetty L DeVroom; Alexander O Vortmeyer; Constantine A Stratakis; Lynnette K Nieman; Edward H Oldfield Journal: J Neurosurg Date: 2009-09 Impact factor: 5.115
Authors: Ivan Ciric; Jin-Cheng Zhao; Hongyan Du; James W Findling; Mark E Molitch; Roy E Weiss; Samuel Refetoff; William D Kerr; Joel Meyer Journal: Neurosurgery Date: 2012-01 Impact factor: 4.654
Authors: E H Oldfield; J L Doppman; L K Nieman; G P Chrousos; D L Miller; D A Katz; G B Cutler; D L Loriaux Journal: N Engl J Med Date: 1991-09-26 Impact factor: 91.245
Authors: Joseph C T Chen; Aitun P Amar; SooHo Choi; Peter Singer; Wnluam T Couldwell; Martin H Weiss Journal: J Neurosurg Date: 2003-05 Impact factor: 5.115
Authors: Sheri K Palejwala; Andrew R Conger; Amy A Eisenberg; Pejman Cohan; Chester F Griffiths; Garni Barkhoudarian; Daniel F Kelly Journal: Pituitary Date: 2018-12 Impact factor: 4.107
Authors: Elena Y Nadezhdina; Olga Yu Rebrova; Andrey Y Grigoriev; Oksana V Ivaschenko; Vilen N Azizyan; Galina A Melnichenko; Ivan I Dedov Journal: Pituitary Date: 2019-12 Impact factor: 4.107
Authors: Przemysław Witek; Grzegorz Zieliński; Katarzyna Szamotulska; Maria Maksymowicz; Grzegorz Kamiński Journal: Eur J Endocrinol Date: 2016-01-25 Impact factor: 6.664
Authors: Regin Jay Mallari; Jai Deep Thakur; Garni Barkhoudarian; Amy Eisenberg; Amanda Rodriguez; Sarah Rettinger; Pejman Cohan; Lynnette Nieman; Daniel F Kelly Journal: J Clin Endocrinol Metab Date: 2022-01-01 Impact factor: 5.958